SRSF1-IN-1

Description

SRSF1-IN-1 STP2 is a SRSF1 inhibitor that regulates the splicing of Bcl-x precursor mRNA by inhibiting SRSF1 expression. SRSF1-IN-1 exhibits anti-tumor activity both in vitro and in vivo, with IC50 values ranging from 0.33 to 6.93 ?M against tumor cells such as HepG2 and MCF7. In mice, SRSF1-IN-1 demonstrates good safety, as intraperitoneal injection at 1 g/kg does not cause death or pathological damage. SRSF1-IN-1 holds promising potential for research in the field of anti-tumor therapy.